Literature DB >> 28950311

Cause-specific death after surgical resection for early-stage non-small-cell lung cancer.

Anders Standal Bugge1,2, May Brit Lund2,3, Morten Valberg4, Odd Terje Brustugun5, Steinar Solberg1,2, Johny Kongerud2,3.   

Abstract

OBJECTIVES: Surgical resection is the recommended treatment for patients with early-stage non-small-cell lung cancer. However, it is believed that causes other than lung cancer can lead to death following surgical resection. Investigating the risk factors for overall mortality and analysing the specific causes of death may indicate the degree of influence of other causes of death.
METHODS: We assessed individual risk factors affecting overall and cause-specific mortality in a Cox proportional hazards model in a cohort of patients with resected Stage I/II non-small-cell lung cancer (n = 756) from 2007 to 2015 in a tertiary university centre. The follow-up period ranged from 3 days to 9.3 years. Median survival time was 7.3 years (95% confidence interval 6.0-7.9). A few patients died of cardiovascular disease (n = 19) and were included in the group 'other cause'. In a competing risk model, we evaluated the risk factors for specific causes of death in patients dying of lung cancer and dying of non-lung cancer specific conditions.
RESULTS: The overall survival was 94%, 62% and 50% at 1, 5 and 7 years, respectively. At the end of the follow-up period, the risk of having died of, respectively, lung cancer or other causes was 36% and 24%. The cumulative incidence of death of lung cancer increased continuously during the study. Risk factors predicting death of all causes and death of non-small-cell lung cancer were increasing age, severely reduced lung function, Eastern Cooperative Oncology Group Performance Status ≥2, preoperative examination without positron emission tomography/computed tomography, histological tumour diagnosis other than adenocarcinoma and squamous cell carcinoma and increasing disease stage. In patients dying of other causes, age, gender, body mass index, smoking and Eastern Cooperative Oncology Group Performance Status ≥2 affected the mortality rate.
CONCLUSIONS: The probability of having died of lung cancer continued to increase beyond 5 years after the operation. Surveillance of risk factors associated with an increased mortality rate should be considered in the postoperative follow-up examination after lung cancer resection.
© The Author 2017. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Cause-specific mortality; Competing risk; Lung cancer; Mortality; NSCLC; Survival; Thoracic oncology; Thoracic surgery

Mesh:

Year:  2018        PMID: 28950311     DOI: 10.1093/ejcts/ezx274

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  13 in total

1.  Competing Risk Analysis in Lung Cancer Patients Over 80 Years Old Undergoing Surgery.

Authors:  Haruaki Hino; Takahiro Karasaki; Yukihiro Yoshida; Takeshi Fukami; Atsushi Sano; Makoto Tanaka; Yoshiaki Furuhata; Kosuke Kashiwabara; Junji Ichinose; Mitsuaki Kawashima; Jun Nakajima
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

2.  Impact of Postoperative Pneumonia Developing After Discharge on Long-Term Follow-up for Resected Lung Cancer.

Authors:  Shuichi Shinohara; Masakazu Sugaya; Takamitsu Onitsuka; Kazuhiko Machida; Masaki Matsuo; Fumihiro Tanaka
Journal:  World J Surg       Date:  2018-12       Impact factor: 3.352

Review 3.  The role of metformin on lung cancer survival: the first systematic review and meta-analysis of observational studies and randomized clinical trials.

Authors:  Tatiana Natasha Toporcov; Elisabete Weiderpass; Suzan Brancher; Ana Elisa Ribeiro
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-15       Impact factor: 4.553

4.  Increase in curative treatment and survival of lung cancer in Norway 2001-2016.

Authors:  Steinar Solberg; Yngvar Nilssen; Odd Terje Brustugun; Tom Kristian Grimsrud; Per Magnus Haram; Nina Helbekkmo; Åslaug Helland; Harald Harris Hjelde; Bjørn Jakobsen; Bjørn Møller; Martin Petersen; Trond-Eirik Strand; Sissel Gyrid Freim Wahl; Marianne Aanerud; Lars Fjellbirkeland
Journal:  Eur J Epidemiol       Date:  2019-07-16       Impact factor: 8.082

5.  Significant diaphragm elevation suggestive of phrenic nerve injury after thoracoscopic lobectomy for lung cancer: an underestimated problem.

Authors:  Luigi Ventura; Weigang Zhao; Tangbing Chen; Zhexin Wang; Jian Feng; Zhitao Gu; Chunyu Ji; Wentao Fang
Journal:  Transl Lung Cancer Res       Date:  2020-10

6.  Implications of Preoperative Transbronchial Lung Biopsy for Non-small Cell Lung Cancer Less than 3-cm.

Authors:  Motoaki Yasukawa; Takeshi Kawaguchi; Michitaka Kimura; Takashi Tojo; Shigeki Taniguchi
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

7.  Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial.

Authors:  Conor E Steuer; Opeyemi A Jegede; Suzanne E Dahlberg; Heather A Wakelee; Steven M Keller; William J Tester; David R Gandara; Stephen L Graziano; Alex A Adjei; Charles A Butts; Suresh S Ramalingam; Joan H Schiller
Journal:  J Thorac Oncol       Date:  2021-02-01       Impact factor: 20.121

8.  The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery.

Authors:  Åsa Kristina Öjlert; Ann Rita Halvorsen; Daniel Nebdal; Marius Lund-Iversen; Steinar Solberg; Odd Terje Brustugun; Ole Christian Lingjaerde; Åslaug Helland
Journal:  Mol Oncol       Date:  2019-04-10       Impact factor: 6.603

9.  The Change Trend of Cause of Death in Patients With Stage I Non-Small Cell Lung Cancer After Surgery in US: A Long-Term Follow-Up Study Based on SEER Database.

Authors:  Wan-da Peng; Jun Xie; Xian Zhang; Chong Li
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

10.  Chronic Progression of Lung Cancer Recurrence After Surgery: Warning Role of Postoperative Pneumonia.

Authors:  Dong-Qi Lin; Jin-Guo Zhu; Xiao-Hua Xu; Ke Xiao; Xu-Qing Wen; Qi-Fa Zheng; Yu-Hua Zhou; Xin-Ying Cai
Journal:  Cancer Manag Res       Date:  2021-09-24       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.